NeurAxis, Inc.

Contributing Author

Recent Articles by NeurAxis, Inc.

Aug-11	NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth NRXS -7.57% GlobeNewswire
Aug-04	NeurAxis Expands Payer Coverage with New Policies NRXS +6.37% GlobeNewswire
Jul-28	NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026 NRXS GlobeNewswire
May-12	NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth NRXS GlobeNewswire
May-05	NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026 NRXS GlobeNewswire
Apr-22	NeurAxis Expands Payer Coverage with Four New Medical Policies NRXS GlobeNewswire
Apr-10	NeurAxis, Inc. Announces Preferred Stock Dividend NRXS -5.66% GlobeNewswire
Mar-19	NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results NRXS GlobeNewswire
Mar-12	NeurAxis to Host Fourth Quarter and Full Year 2025 Results and Business Update Call on Thursday, March 19, 2026 NRXS GlobeNewswire
Jan-08	NeurAxis Achieves Major Milestone with AMA Category I CPT Code Now in Effect, Establishing a Permanent Reimbursement Pathway NRXS GlobeNewswire
Dec-19	NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives NRXS +11.81% GlobeNewswire
Dec-01	NeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional Abdominal Pain NRXS GlobeNewswire
Nov-12	NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives NRXS +7.88% GlobeNewswire
Nov-11	NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues NRXS -5.86% GlobeNewswire
Nov-04	NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025 NRXS -5.22% GlobeNewswire
Oct-24	NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population NRXS -8.64% GlobeNewswire
Sep-18	NeurAxis to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 NRXS GlobeNewswire
Aug-12	NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues NRXS GlobeNewswire
Aug-05	NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025 NRXS GlobeNewswire
Jun-17	NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives NRXS GlobeNewswire
Jun-10	NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBS NRXS -8.65% GlobeNewswire
May-27	NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 NRXS GlobeNewswire
May-22	NeurAxis Announces Closing of $5.0 Million Registered Direct Offering NRXS -5.31% GlobeNewswire
May-21	NeurAxis Announces $5.0 Million Registered Direct Offering NRXS -19.80% GlobeNewswire
May-20	NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms NRXS +75.77% GlobeNewswire
May-12	NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues NRXS +16.00% GlobeNewswire
May-05	NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025 NRXS -11.64% GlobeNewswire

NeurAxis, Inc.

Recent Articles by NeurAxis, Inc.

Upgrade your Finviz experience